期刊文献+

血液透析患者血清肿瘤标志物的检测及临床意义 被引量:9

Detection and Clinical Value of Serum Tumor Markers in Hemodialysis Patients
下载PDF
导出
摘要 目的:观察血液透析(血透)患者血清肿瘤标志物CEA、CA19-9、NSE、CA242、Ferritin、β-HCG、AFP、HGH、CA153、CA125、PSA、fPSA的临床意义。方法:选择143例维持性血透患者作为血透组、143例未行血透的尿毒症患者(CKD5期)作为非透析组,并选择429例健康人作为对照组。将血透组按血透维持时间分为两个亚组比较:A组,维持性透析时间超过3月;B组,维持性透析时间少于3月。结果:血透组和非透析组比较,Ferritin水平差异有统计学意义,其他各肿瘤标志物水平差异无统计学意义(P>0.05);血透组、非透析组与对照组比较肿瘤标志物Ferritin、CA19-9、CA125的水平差异有统计学意义(P<0.05);其他肿瘤标志物的差异无统计学意义(P>0.05)。透析组的两个亚组肿瘤标志物水平差异无统计学意义。结论:尿毒症和血透患者肿瘤标志物Ferritin、CA19-9、CA125有不同程度的升高,血透不能清除肿瘤标志物。 Objective:To assesses the clinical value of tumor markers including CEA,CA19-9,NSE,CA242,Ferritin,β-HCG,AFP,HGH,CA153,CA125,PSA,and fPSA in haemodialysis patients.Methods:We assigned 143 patients receiving maintenance hemodialysis into the hemodialysis group,143 patients with uremia who did not receive hemodialysis into the non-hemodialysis group,and 429 healthy people into the control group.Patients in hemodialysis group were further divided into two subgroups according to the duration of hemodialysis,and serum levels of tumor markers were compared between the two subgroups.Results:There were statistically significant differences in Ferritin,but not in any of the other tumor markers between hemodialysis and non-hemodialysis groups(P〉0.05).The serum levels of CA199,CA125 and Ferritin in two groups and the control groups had statistical significance(P〈0.05).There were no significant differences in serum levels of other tumor markers(P〉0.05).There were no significant differences in serum levels of any tumor marker between two subgroups within hemodialysis group.Conclusion:Ferritin,CA19-9 and CA125 were elevated to various degrees in patients with uremia who were receiving hemodialysis or not receiving hemodialysis.Hemodialysis was not to eleminate tumor markers.
出处 《中国中西医结合肾病杂志》 2010年第4期318-321,共4页 Chinese Journal of Integrated Traditional and Western Nephrology
关键词 肿瘤标志物 尿毒症 血液透析 Tumor markers Uremia Hemodialysis
  • 相关文献

参考文献18

  • 1Weinberger SR,Dalmasso EA,Fung ET.Current achievenaents using Protein Chip Array technology.Curr Opin China Biol,2002,6(1):86-91.
  • 2Sun Z,Fu X,Zhang L,et al.A protein chip system for parallel analysis of multi-tumor markers and its application in cancer detection.Anticancer Res,2004,24 (2C):1159-1165.
  • 3Xiao WB,Liu YL.Elevation of serum and ascites cancer antigen 125 levels in patients with liver cirrhosis.J Gastroenterol Hepatol,2003,18(11):1315-1316.
  • 4Sevinc A,Buyukberber S,Sari R,et al.Elevated serum CA125 levels in patients with nephrotic syndrome-induced ascites.Anticancer Res,2000,20(2B):1201-1203.
  • 5Odagiri E,Jibiki K,Takeda M,et al.Effect of hernodialysis on the concentration of the seven tumor markers carcinoembryonic antigen,alpha-fetoprotein,squamous cell carcinoma-related antigen,neuron-specific enolase,CA125,CA199 and CA153 in uremic patients.Am J Nephrol,1991,11 (5):363.
  • 6Lye WC,Tarnbyah P,Leong SO,et al.Serum tumor markers in patients on dialysis and kidney transplantation.Adv Petit Dial,1994,10:109-111.
  • 7Bastani B,Chu N.Serum CA-125 level in end-stage renal disease patients maintained on chronic peritoneal dialysis or hemodialysis:the effect of continuous presence of peritoneal fluid,peritonitis and peritoneal catheter implantation.Am J Nephrol,1995,15 (6):468-472.
  • 8Grzegorzewska AE,Mlot M,Leande M,et al.Serum levels of cancer antigen 125 and interleukin-15 in relation to the nutrition status of peritoneal dialysis patients.Adv Petit Dial,2004,20:185-189.
  • 9Arik N,Adam B,Akpolat T.Serum tumor markers in renal failure.Int Urol Nephrol,1996,28(4):601 -604.
  • 10俞小芳,徐夏莲,叶志斌,吴兆龙.肾功能及血液透析对慢性肾脏疾病患者血清肿瘤标志物的影响[J].上海医学,2007,30(2):81-85. 被引量:8

二级参考文献25

  • 1张悦,叶志斌,吉俊.肿瘤标记物在原发性肾脏疾病患者中的血清学浓度改变[J].中国临床医学,2005,12(1):135-137. 被引量:10
  • 2黄继义,江德文,张燕林.癌抗原125检测在慢性肾功能衰竭血液透析患者中的临床意义[J].中华肾脏病杂志,2006,22(9):582-582. 被引量:8
  • 3俞小芳,徐夏莲,叶志斌,吴兆龙.肾功能及血液透析对慢性肾脏疾病患者血清肿瘤标志物的影响[J].上海医学,2007,30(2):81-85. 被引量:8
  • 4Nomura F,Koyama A,Ishijima M,et al.Serum levels of five tumor markers for lung cancer in patients with chronic renal failure.Oncol Rep,1998,5:389-392.
  • 5Filella X,Cases A,Molina R,et al.Tumor markers in patients with chronic renal failure.Int J Biol Markers,1990,5:85-88.
  • 6Arik N,Adam B,Akpolat T,et al.Serum tumour markers in renal failure.Int Urol Nephrol,1996,28:601-604.
  • 7Harper L,McIntyre CW,MacDougall IC,et al.Prostate-specific antigen levels in patients receiving long-term dialysis.Br J Urol,1995,76:482-483.
  • 8Sumura M,Yokogi H,Beppu M,et al.Diagnostic value of serum prostate-specific antigen in hemodialysis patients.Int J Urol,2003,10:247-250.
  • 9Bruun L,Bjork T,Lilja H,et al.Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.Nephrol Dial Transplant,2003,18:598-603.
  • 10Sasagawa I,Kubota Y,Hayami S,et al.Serum levels of total and free prostate specific antigen in men on hemodialysis.J Urol,1998,160:83-85.

共引文献9

同被引文献42

引证文献9

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部